Table 1.
Indication for systemic treatment according to severity and high-risk features of chronic GVHD
| NIH Global severity | Maximal severity in all organs | Number of organs | High-risk featurea | Systemic treatment |
|---|---|---|---|---|
| Mild | 1 (0 for lung) | ≤ 2 | Absent | No |
| Present | Yesb | |||
| Moderate | 1 (0 for lung) | ≥ 3 | Present or absent | Yesb |
| 2 (1 for lung) | Any | |||
| Severe | 3 (2 for lung) | Any | Present or absent | Yes |
a
Thrombocytopenia <100 × 103/μl, progressive onset, or total serum bilirubin >2 mg/dL at onset.
b
The benefits of graft-versus-tumor effect and the risk of chronic GVHD require careful consideration particularly for patients with high risk of recurrent malignancy.